Publicaciones en las que colabora con Bruno Paiva (18)

2024

  1. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  2. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells

    British Journal of Haematology, Vol. 205, Núm. 4, pp. 1346-1355

2023

  1. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924

2022

  1. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

  2. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  3. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

    Blood Advances, Vol. 6, Núm. 2, pp. 690-703

2021

  1. Immunologic characterization of COVID-19 patients with hematological cancer

    Haematologica

  2. Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients

    Frontiers in Immunology, Vol. 12

2020

  1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  2. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

2019

  1. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

    OncoImmunology, Vol. 8, Núm. 7

  2. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

  3. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187

2018

  1. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: The role of occult pre-existing autoimmunity

    Haematologica

  2. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

    Blood cancer journal, Vol. 8, Núm. 12, pp. 117

2017

  1. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

    Cancer Cell, Vol. 31, Núm. 3, pp. 396-410

2016

  1. Utility of flow cytometry studies in the management of patients with multiple myeloma

    Current Opinion in Oncology, Vol. 28, Núm. 6, pp. 511-517

2015

  1. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

    Leukemia